# US 2022/0276171 A1 · Composition and method for monitoring lipid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276171 A1
- Document ID: US20220276171A1
- Status: Published application
- Kind: A1
- Application number: 17/497,325
- Filed: 2021-10-08
- Published: 2022-09-01
- Earliest claimed: 2014-05-28
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan-Kettering Cancer Center
- Inventors: Prakrit JENA; Daniel A. HELLER; Daniel ROXBURY
- Web page: https://patentgrep.com/patent/US20220276171A1

## CPC

- G01N 21/6489: {Photoluminescence of semiconductors}
- A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes}
- A61B 5/1455: using optical sensors, e.g. spectral photometrical oximeters
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 15/00: Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- G01N 21/6486: {Measuring fluorescence of biological material, e.g. DNA, RNA, cells (G01N21/6428 takes precedence)}
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SW-CNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.

## Claims

### Claim 1

A method of detecting a condition in a subject using single-walled carbon nanotubes (SWCNTs), comprising:
contacting cells of said subject with SWCNTs;
monitoring photoluminescence emitted by SWCNTs internalized into said cells and generating an SWCNT emission profile;
comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result; and
determining a likelihood of having said condition in said subject based on the result from said comparing step.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the SWCNTs are semi-conductive SWCNTs.

### Claim 5 (depends on 1)

The method of claim 1, wherein the SWCNTs are oligonucleotide-coated non-covalently encapsulated SWCNTs.

### Claim 6 (depends on 1)

The method of claim 1, wherein the SWCNTs are encapsulated by DNA oligonucleotides, optionally the DNA oligonucleotides are ss(GT)6 oligonucleotides.

### Claim 7 (depends on 1)

The method of claim 1, wherein the SWCNTs have chiral indices (n,m) of (6,5) or (8,6).

### Claim 8 (depends on 1)

The method of claim 1, wherein the SWCNTs are purified (8,6) SWCNTs encapsulated with ss(GT)6 oligonucleotides.

### Claim 9 (depends on 1)

The method of claim 1, wherein the condition is a disease linked to elevated lipid and cholesterol content and wherein a blue-shift in the SWCNT emission profile from the control emission profile is an indication of the present of the condition in the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the condition is atherosclerosis, fatty liver disorder or cancer.

### Claim 11 (depends on 9)

The method of claim 9, wherein the condition is hypercholesterolemia.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cells contacted with SWCNTs are cultured in vitro.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cells contacted with SWCNTs are fibroblasts, microphages or hepatocytes.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cells contacted with SWCNTs are located in a subject in vivo.

### Claim 15 (depends on 1)

The method of claim 1, further comprising the step of:
extracting cells from the subject; and
culturing the extracted cells in vitro to produce culture cells,
wherein the cells contacted with SWCNTs are the cultured cells from the culturing step.

### Claim 16 (depends on 3)

The method of claim 3, wherein the sample is a biological sample.

### Claim 17 (depends on 16)

The method of claim 16, wherein the sample is a plasma sample.

### Claim at position 18

18-22. (canceled)

### Claim 23

A kit for detecting changes in lipid accumulation, comprising:
SWCNTs; and
oligonucleotides suitable for encapsulating SWCNTs.

### Claim 24 (depends on 23)

The kit of claim 23, wherein the SWCNTs are (8,6) carbon nanotubes and the oligonucleotides are ss(GT)6 oligonucleotides.
